Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Change in Receivables (2019 - 2025)

BioNexus Gene Lab's Change in Receivables history spans 7 years, with the latest figure at -$206475.0 for Q3 2025.

  • For Q3 2025, Change in Receivables fell 34.71% year-over-year to -$206475.0; the TTM value through Sep 2025 reached $460258.0, down 54.24%, while the annual FY2024 figure was $147760.0, 77.3% down from the prior year.
  • Change in Receivables for Q3 2025 was -$206475.0 at BioNexus Gene Lab, down from $480950.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $1.2 million in Q4 2022 and bottomed at -$402845.0 in Q1 2021.
  • The 5-year median for Change in Receivables is -$112473.0 (2024), against an average of $109383.8.
  • The largest annual shift saw Change in Receivables crashed 345.95% in 2021 before it surged 713.03% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $777770.0 in 2021, then surged by 51.34% to $1.2 million in 2022, then fell by 1.75% to $1.2 million in 2023, then crashed by 74.2% to $298398.0 in 2024, then crashed by 169.19% to -$206475.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Change in Receivables are -$206475.0 (Q3 2025), $480950.0 (Q2 2025), and -$112615.0 (Q1 2025).